ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD)
CAPS Rating:
The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.
RSS Headlines
Fool UK
Recs
No catalyst for awhile. And second phase 3 isn't a sure thing. Placebo effect is hard to beat twice.